Pulmonary embolism in a patient with multiple myeloma receiving thalidomide–dexamethasone therapy
- 111 Downloads
Massive pulmonary embolism is an uncommon complication of multiple myeloma treated with thalidomide–dexamethasone regimen. In 2006, multiple myeloma was diagnosed in a 72-year-old man, who received thalidomide–dexamethasone therapy. In January 2007, echocardiography and computerized tomography identified massive pulmonary embolism in the pulmonary arteries and a deep vein thrombus of the right leg. The patient also had an elevated concentration of B-type natriuretic peptide. After heparinization and warfarin therapy, the patient’s condition improved. This is the first report of a patient with a rare complication of pulmonary embolism from thalidomide-treated multiple myeloma.
KeywordsMultiple myeloma Pulmonary embolism Thalidomide
Dr Chu is supported by NHRI, Taiwan (NHRI-EX91-9108SC, NHRI-EX92-9108SC, NHRI-EX-93-9108SC, NHRI-EX94-9108SC, NHRI-EX54-9108SCl, and NHRI-EX96-9627SI), CMRPG32057 from the Chang Gung Memorial Hospital, the NSC Memorial Hospital, and the National Sciences Council (NSC 94-2314-B-182-071 and 95-2314-B-182-021).
- 13.Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR, The Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24:431–6.PubMedCrossRefGoogle Scholar
- 16.Pieralli F, Olivotto I, Vanni S, Conti A, Camaiti A, Targioni G, et al. Usefulness of bedside testing for brain natriuretic peptide to identify right ventricular dysfunction and outcome in normotensive patients with acute pulmonary embolism. Am J Cardiol. 2006;97:1386–90.PubMedCrossRefGoogle Scholar
- 22.Raje N, Powles R, Kulkarni S, Milan S, Middleton G, Singhal S, et al. A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. Br J Haematol. 1997;97:153–60.PubMedCrossRefGoogle Scholar